Russian strategy in Ukraine under pressure. Longer term impact of military action on economy

Emerging markets will dominate global growth - where 85% of humanity lives. Economy keynote speaker

Trust is the most important thing. Future of logistics and supply chain management - keynote speaker

Future of Sales and Marketing beyond COVID - hybrid event in Vilnius: physical audience of 800 + 300 virtual. Digital marketing, location marketing. How to create MAGIC in new marketing campaigns. Future of Marketing Keynote Speaker

Chances of 2 people in 70 having same birthday? Managing Risk in Banking and Financial Services. Why the greatest risks are combinations of very unlikely events, which happen far more often than you expect. Keynote speaker on risk management

Compliance is Dead. How to build trust. Reputation of banks and financial services. Compliance Risks. Why 100% compliance with regulations, ESG requirements etc is often not enough to prevent reputational damage

Life's too short to do things you don't believe in! Why passionate belief in the true value of what you are selling or doing is the number one key to success. Secret of all leadership and marketing - keynote for 1100 people in Vilnius October 2021

Why you can't innovate on Zoom or Teams meetings - Innovation is almost impossible unless breathing same air, in same room

Why the key to rapid innovation is team diversity - survey global CEOs. Innovation keynote speaker

Future Manufacturing 5.0. Lessons from personal life for all manufacturers. Manufacturing Keynote

Future of Manufacturing: diagnostics; predictive analytics, little data and cybersecurity. Keynote

Manufacturing 5 0: The truth about robots, robotics and automation. Future of Manufacturing Keynote

STI571 hope of new cure for bone cancer

Futurist Keynote Speaker: Posts, Slides, Videos - Future Health Care and Pharma Keynote Speaker

What is the truth about STI571?  Does STI571 cure cancer?  STI571 side effects.  Summary of latest research and news on STI571 by Dr Patrick Dixon MA MBBS.  Please not that STI571 is often mispelled as ST1571, especially by those looking on the net.

STI571 is a new cancer drug which appears to have sent 95% of patients with CML (chronic myeloid leukaemia or chronic myelogenous leukemia) into remission in early trials.  In one UK trial 30 out of 31 people had white blood cell counts which returned to normal after a month on STI571 while the final patient's blood count also became normal soon after.

All 31 patients were selected from the 50% of all patients with CML who are sensitive to the STI571. Eleven showed significant improvement and three of those eleven cleared their bone marrow of leukaemic cells completely. 

Side effects seem very few from the daily STI571 tablet, certainly a lot less than bone marrow transplant or interferon.

Now Novartis who makes STI571 is under pressure together with the regulatory authorities to bring the drug to market as quickly as possible.  The US licence application for STI571 is imminent.  The US Food and Drug Administration have agreed to an "accelerated STI571 approval" which means the drug will undergo only two rounds of tests, not three.

Chronic myeloid leukaemia is diagnosed in around 1,000 people each year in the UK. It is caused by the Philadelphia chromosome - an abnormality that arises when part of one chromosome becomes attached to another.  STI571 works by blocking enzymes only used in these cancer cells.

Related news items:
Newer news items:
Older news items:

Thanks for promoting with Facebook LIKE or Tweet. Really interested to read your views. Post below.

Emanuel Turchetto
June 08, 2011 - 23:50

It seems that the drug STI571 needs do be accompained by antibiotica or a human natura sort of protein is going to attack the pills hormon before this can penetrated the cancerous cells. Italian scientists have apparently found out this trick.

October 22, 2010 - 02:22
Fly the ribbon

Could you please let me know how to get a pink breast cancer ribbon on my facebook page?

Join the Debate! What are your own views?



Search for your future

Our cookie policy

We use cookies for statistical purposes. To comply with the e-Privacy Directive we need to ask your consent to place these cookies on your computer.

Your use of this site indicates acceptance of these terms. I accept